Avigan, the antiviral therapy approved to treat COVID-19 in Russia, China, Bangladesh, and other nations, and under investigation in the United States, now makes its way to the Philippines. Now under review for registration in Japan, the antiviral originally from Japan and known as Favipiravir was given the green light by the Department of Health (DOH) in the Philippines. Maria Rosario Vergeire, Undersecretary for DOH, declared the study should be able to proceed next week, pending some final document processing. The nine-month study will occur at four hospitals, including Philippine General Hospital, Sta. Ana Hospital, Dr. Jose N. Rodriguez Memorial Hospital, and Quirino Memorial Medical Center.
TrialSite has chronicled fairly extensively the Favipiravir studies in the U.S. and beyond. The question was asked, why wasn’t there more discussion about this antiviral therapy given the U.S. Department of Defense spent over $200 million on clinical trials in the U.S. just five years ago?
The Philippines Study
The DOH reported that a study will recruit about 100 patients for the effort. The study was supposed to start in July, but has been in delay due to many legal and compliance documentation, reports the Manilla Bulletin.